8 completed, 8 unknown, 5 recruiting, 3 active not recruiting. 18 Phase 2, 3 Phase 3, 1 Phase 1, 1 Phase 4.
Follow Langerhans Cell Histiocytosis: new trials by email Literature Review of Langerhans Cell Histiocytosis trials Research Report on Langerhans Cell Histiocytosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Response-adapted Luvometinib With or Without Cytarabine in Langerhans Cell Histiocytosis Luvometinib, Luvometinib, Cytarabine. - Langerhans Cell Histiocytosis | Phase 2 | Not yet recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 30 | 2026-06-30 | 2026-07-27 |
| Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCH Cytarabine (Ara-C), Thalidomide (100mg) - Langerhans Cell Histiocytosis | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 50 | 2025-04-12 | 2025-09-22 |
| Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib Trametinib - Langerhans Cell Histiocytosis | Phase 2 | Recruiting | Cook Children's Health Care System | 75 | 2024-06-24 | 2026-04-07 |
| To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH FCN-159 - Langerhans Cell Histiocytosis, LCH | Phase 2 | Recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 56 | 2023-09-28 | 2025-01-24 |
| Safety and Efficacy of CD207 Targeted CAR-T Cell Therapy in Patients With R/R Langerhans Cell Histiocytosis CD207 CAR-T cells - Langerhans Cell Histiocytosis | Phase 1 | Unknown | Beijing Friendship Hospital | 12 | 2022-10-01 | 2022-07-28 |
| Histiocytic Disorder Follow-up Study Histiocytosis, Langerhans Cell Histiocytosis | Recruiting | University of Alabama at Birmingham | 6000 | 2022-09-01 | 2026-06-12 | |
| The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation HLX208 - Langerhans Cell Histiocytosis, Erdheim-Chester Disease | Phase 2 | Unknown | Shanghai Henlius Biotech | 25 | 2021-12-06 | 2023-08-08 |
| LCH in Adults: a Collaborative, Prospective-retrospective, Observational Study Data collection - Langerhans Cell Histiocytosis | Unknown | Gruppo Italiano Malattie EMatologiche dell'Adulto | 186 | 2021-03-15 | 2024-02-07 | |
| Thalidomide, Cyclophosphamide and Dexamethasone for Recurrent/Refractory Adult Langerhans Cell Histiocytosis thalidomide combined with dexamethasone and cyclophosphamide - Langerhans Cell Histiocytosis | Phase 2 | Unknown | Peking Union Medical College Hospital | 20 | 2019-10-10 | 2021-06-08 |
| AraC for Newly Diagnosed Adult Langerhans Cell Histiocytosis Cytarabine - Langerhans Cell Histiocytosis | Phase 2 | Unknown | Peking Union Medical College Hospital | 40 | 2019-10-01 | 2021-06-08 |
| A Prospective Study for the Treatment of Children With Newly Diagnosed LCH Using a Cytarabine Contained Protocol Prednisone+Cytarabine+vincristine, Prednisone+Cytarabine+vincristine+Mercaptopurine, Prednisone+vincristine+Mercaptopurine - Langerhans Cell Histiocytosis | Phase 3 | Unknown | Shanghai Children's Medical Center | 200 | 2018-07-01 | 2022-07-26 |
| A Combination of Vemurafenib, Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E Mutation Vemurafenib, Cytarabine, 2-chlorodeoxyadenosine - Langerhans Cell Histiocytosis | Phase 2 | Unknown | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 12 | 2018-06-26 | 2023-03-16 |
| Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Vemurafenib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 4 | 2017-11-08 | 2025-01-27 |
| Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma Anti-Thymocyte Globulin, Busulfan, Clofarabine - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 6 | 2017-10-13 | 2023-10-11 |
| Denosumab for the Treatment of Adult LCH Denosumab 70 MG/ML [Xgeva] - Langerhans Cell Histiocytosis | Phase 2 | Completed | Hellenic Society for the Study of Bone Metabolism | 10 | 2017-09-07 | 2025-01-15 |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1377 | 2017-07-31 | 2026-07-24 |
| LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis Prednisone, Vinblastine, mercaptopurine - Langerhans Cell Histiocytosis | Phase 2 / Phase 3 | Active not recruiting | North American Consortium for Histiocytosis | 1400 | 2016-11-02 | 2026-04-09 |
| Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH) Cytarabine, Vinblastine/prednisone - Langerhans Cell Histiocytosis | Phase 3 | Recruiting | Baylor College of Medicine | 124 | 2016-03-07 | 2025-09-11 |
| Evaluation of Exercise Capacity and Exercise Limitation in Patients With Pulmonary Langerhans Cell Histiocytosis Langerhans Cell Histiocytosis | Completed | InCor Heart Institute | 35 | 2016-03-01 | 2019-03-01 | |
| Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement F-choline PET Scan, FDG-PET, biopsy - Erdheim-Chester Disease, Langerhans Cell Histiocytosis | Completed | Memorial Sloan Kettering Cancer Center | 3 | 2015-11-01 | 2018-08-29 |
Showing 20 of 26. Sign in to see all of them.
Histiocytosis, Langerhans-Cell (26) · Erdheim-Chester Disease (3) · Lymphoma, Non-Hodgkin (3) · Central Nervous System Neoplasms (2) · Ependymoma (2) · Glioma (2) · Hepatoblastoma (2) · Histiocytic Sarcoma (2) · Histiocytosis (2) · Histiocytosis, Sinus (2) · Neuroblastoma (2) · Neuroectodermal Tumors, Primitive, Peripheral (2) · Osteosarcoma (2) · Rhabdoid Tumor (2) · Rhabdomyosarcoma (2)
Hemic and Lymphatic Diseases (26) · Lung Diseases (26) · Lung Diseases, Interstitial (26) · Lymphatic Diseases (26) · Respiratory Tract Diseases (26) · Histiocytosis (24) · Histiocytosis, Non-Langerhans-Cell (5) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphoma (3) · Lymphoproliferative Disorders (3) · Pathological Conditions, Signs and Symptoms (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2)
Cytarabine (7) · Clofarabine (3) · Methotrexate (3) · Prednisone (3) · Vemurafenib (3) · Biopsy (2) · Cladribine (2) · Cyclophosphamide (2) · Vinblastine (2) · Antilymphocyte Serum (1) · Busulfan (1) · CCT239065 (1) · CT-P10 (1) · Cord Blood Stem Cell Transplantation (1) · Data Collection (1)
Peking Union Medical College Hospital (3) · Dana-Farber Cancer Institute (2) · Memorial Sloan Kettering Cancer Center (2) · National Cancer Institute (NCI) (2) · Baylor College of Medicine (1) · Beijing Friendship Hospital (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Cook Children's Health Care System (1) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1) · GlaxoSmithKline (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Hellenic Society for the Study of Bone Metabolism (1) · InCor Heart Institute (1) · M.D. Anderson Cancer Center (1) · North American Consortium for Histiocytosis (1)
United States (11) · China (10) · Canada (2) · Puerto Rico (2) · Australia (1) · Brazil (1) · Greece (1) · Italy (1) · Russia (1)
AeRang Kim (1) · Amanda Olson (1) · Anish Ray, MD (1) · Barbara Degar, MD (1) · Bruno G Baldi, md, PhD (1) · Carlos Rodriguez-Galindo, MD (1) · Donald W Parsons (1) · Eli Diamond, MD (1) · Gaurav Goyal, MD (1) · Jian Li (1) · Jian Li, MD (1) · Milen Minkov, MD, Ph.D (1) · Olive Eckstein, MD (1) · Polyzois Makras, MD, PhD (1)
PMID 23589673, PMID 29200145, PMID 30693828, PMID 31401903, PMID 32423455, PMID 32615192, PMID 33591402, PMID 35353553, PMID 37216396, PMID 38873934, PMID 41166674, PMID 42126265, PMID 42686334
U10CA180886 (2)